Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 149


Nonlinear mixed effects dose response modeling in high throughput drug screens: application to melanoma cell line analysis.

Ding KF, Petricoin EF, Finlay D, Yin H, Hendricks WPD, Sereduk C, Kiefer J, Sekulic A, LoRusso PM, Vuori K, Trent JM, Schork NJ.

Oncotarget. 2017 Dec 15;9(4):5044-5057. doi: 10.18632/oncotarget.23495. eCollection 2018 Jan 12.


Trastuzumab emtansine: determining its role in management of HER2+ breast cancer.

Doroshow DB, LoRusso PM.

Future Oncol. 2018 Mar;14(7):589-602. doi: 10.2217/fon-2017-0477. Epub 2017 Dec 7.


Precision Medicine: Progress, Pitfalls, and Promises.

Pilié PG, LoRusso PM, Yap TA.

Mol Cancer Ther. 2017 Dec;16(12):2641-2644. doi: 10.1158/1535-7163.MCT-17-0904. No abstract available.


Twenty-First Century Precision Medicine in Oncology: Genomic Profiling in Patients With Cancer.

Borad MJ, LoRusso PM.

Mayo Clin Proc. 2017 Oct;92(10):1583-1591. doi: 10.1016/j.mayocp.2017.08.002. Review.


A Phase 1 study of ARQ 087, an oral pan-FGFR inhibitor in patients with advanced solid tumours.

Papadopoulos KP, El-Rayes BF, Tolcher AW, Patnaik A, Rasco DW, Harvey RD, LoRusso PM, Sachdev JC, Abbadessa G, Savage RE, Hall T, Schwartz B, Wang Y, Kazakin J, Shaib WL.

Br J Cancer. 2017 Nov 21;117(11):1592-1599. doi: 10.1038/bjc.2017.330. Epub 2017 Oct 3.


BET inhibitors: a novel epigenetic approach.

Doroshow DB, Eder JP, LoRusso PM.

Ann Oncol. 2017 Aug 1;28(8):1776-1787. doi: 10.1093/annonc/mdx157.


Erratum to: A phase I dose-escalation study of Selumetinib in combination with Erlotinib or Temsirolimus in patients with advanced solid tumors.

Infante JR, Cohen RB, Kim KB, Burris HA 3rd, Curt G, Emeribe U, Clemett D, Tomkinson HK, LoRusso PM.

Invest New Drugs. 2017 Oct;35(5):669. doi: 10.1007/s10637-017-0479-3. No abstract available.


Trastuzumab emtansine versus treatment of physician's choice in patients with previously treated HER2-positive metastatic breast cancer (TH3RESA): final overall survival results from a randomised open-label phase 3 trial.

Krop IE, Kim SB, Martin AG, LoRusso PM, Ferrero JM, Badovinac-Crnjevic T, Hoersch S, Smitt M, Wildiers H.

Lancet Oncol. 2017 Jun;18(6):743-754. doi: 10.1016/S1470-2045(17)30313-3. Epub 2017 May 16.


A First-in-Human, Phase I, Dose-Escalation Study of TAK-117, a Selective PI3Kα Isoform Inhibitor, in Patients with Advanced Solid Malignancies.

Juric D, de Bono JS, LoRusso PM, Nemunaitis J, Heath EI, Kwak EL, Macarulla Mercadé T, Geuna E, Jose de Miguel-Luken M, Patel C, Kuida K, Sankoh S, Westin EH, Zohren F, Shou Y, Tabernero J.

Clin Cancer Res. 2017 Sep 1;23(17):5015-5023. doi: 10.1158/1078-0432.CCR-16-2888. Epub 2017 May 10.


A phase I dose-escalation study of Selumetinib in combination with Erlotinib or Temsirolimus in patients with advanced solid tumors.

Infante JR, Cohen RB, Kim KB, Burris HA 3rd, Curt G, Emeribe U, Clemett D, Tomkinson HK, LoRusso PM.

Invest New Drugs. 2017 Oct;35(5):576-588. doi: 10.1007/s10637-017-0459-7. Epub 2017 Apr 19. Erratum in: Invest New Drugs. 2017 Jul 5;:.


A phase I dose-escalation study of the safety and pharmacokinetics of a tablet formulation of voxtalisib, a phosphoinositide 3-kinase inhibitor, in patients with solid tumors.

Mehnert JM, Edelman G, Stein M, Camisa H, Lager J, Dedieu JF, Ghuysen AF, Sharma J, Liu L, LoRusso PM.

Invest New Drugs. 2018 Feb;36(1):36-44. doi: 10.1007/s10637-017-0467-7. Epub 2017 Apr 17.


A phase 2 study of vorinostat in locally advanced, recurrent, or metastatic adenoid cystic carcinoma.

Goncalves PH, Heilbrun LK, Barrett MT, Kummar S, Hansen AR, Siu LL, Piekarz RL, Sukari AW, Chao J, Pilat MJ, Smith DW, Casetta L, Boerner SA, Chen A, Lenkiewicz E, Malasi S, LoRusso PM.

Oncotarget. 2017 May 16;8(20):32918-32929. doi: 10.18632/oncotarget.16464.


64Cu-MM-302 Positron Emission Tomography Quantifies Variability of Enhanced Permeability and Retention of Nanoparticles in Relation to Treatment Response in Patients with Metastatic Breast Cancer.

Lee H, Shields AF, Siegel BA, Miller KD, Krop I, Ma CX, LoRusso PM, Munster PN, Campbell K, Gaddy DF, Leonard SC, Geretti E, Blocker SJ, Kirpotin DB, Moyo V, Wickham TJ, Hendriks BS.

Clin Cancer Res. 2017 Aug 1;23(15):4190-4202. doi: 10.1158/1078-0432.CCR-16-3193. Epub 2017 Mar 15.


A phase I dose-escalation study of selumetinib in combination with docetaxel or dacarbazine in patients with advanced solid tumors.

LoRusso PM, Infante JR, Kim KB, Burris HA 3rd, Curt G, Emeribe U, Clemett D, Tomkinson HK, Cohen RB.

BMC Cancer. 2017 Mar 6;17(1):173. doi: 10.1186/s12885-017-3143-6.


Analysis of variability in high throughput screening data: applications to melanoma cell lines and drug responses.

Ding KF, Finlay D, Yin H, Hendricks WPD, Sereduk C, Kiefer J, Sekulic A, LoRusso PM, Vuori K, Trent JM, Schork NJ.

Oncotarget. 2017 Apr 25;8(17):27786-27799. doi: 10.18632/oncotarget.15347.


Phase 1 study of narnatumab, an anti-RON receptor monoclonal antibody, in patients with advanced solid tumors.

LoRusso PM, Gounder M, Jalal SI, André V, Kambhampati SRP, Loizos N, Hall J, Holzer TR, Nasir A, Cosaert J, Kauh J, Chiorean EG.

Invest New Drugs. 2017 Aug;35(4):442-450. doi: 10.1007/s10637-016-0413-0. Epub 2017 Feb 4.


Phase I study of the gamma secretase inhibitor PF-03084014 in combination with docetaxel in patients with advanced triple-negative breast cancer.

Locatelli MA, Aftimos P, Dees EC, LoRusso PM, Pegram MD, Awada A, Huang B, Cesari R, Jiang Y, Shaik MN, Kern KA, Curigliano G.

Oncotarget. 2017 Jan 10;8(2):2320-2328. doi: 10.18632/oncotarget.13727.


Phase I Study of GDC-0425, a Checkpoint Kinase 1 Inhibitor, in Combination with Gemcitabine in Patients with Refractory Solid Tumors.

Infante JR, Hollebecque A, Postel-Vinay S, Bauer TM, Blackwood EM, Evangelista M, Mahrus S, Peale FV, Lu X, Sahasranaman S, Zhu R, Chen Y, Ding X, Murray ER, Schutzman JL, Lauchle JO, Soria JC, LoRusso PM.

Clin Cancer Res. 2017 May 15;23(10):2423-2432. doi: 10.1158/1078-0432.CCR-16-1782. Epub 2016 Nov 4.


Inhibition of the PI3K/AKT/mTOR Pathway in Solid Tumors.

LoRusso PM.

J Clin Oncol. 2016 Nov 1;34(31):3803-3815. doi: 10.1200/JCO.2014.59.0018. Epub 2016 Sep 30. Review.


Qualitative Analysis of the Experience of Mental Fatigue of Family Caregivers of Patients With Cancer in Phase I Trials.

Weiss DM, Northouse LL, Duffy SA, Ingersoll-Dayton B, Katapodi MC, LoRusso PM.

Oncol Nurs Forum. 2016 Jul 1;43(4):E153-60. doi: 10.1188/16.ONF.E153-E160.


Integrating Dynamic Positron Emission Tomography and Conventional Pharmacokinetic Studies to Delineate Plasma and Tumor Pharmacokinetics of FAU, a Prodrug Bioactivated by Thymidylate Synthase.

Li J, Kim S, Shields AF, Douglas KA, McHugh CI, Lawhorn-Crews JM, Wu J, Mangner TJ, LoRusso PM.

J Clin Pharmacol. 2016 Nov;56(11):1433-1447. doi: 10.1002/jcph.751.


A first in man, dose-finding study of the mTORC1/mTORC2 inhibitor OSI-027 in patients with advanced solid malignancies.

Mateo J, Olmos D, Dumez H, Poondru S, Samberg NL, Barr S, Van Tornout JM, Jie F, Sandhu S, Tan DS, Moreno V, LoRusso PM, Kaye SB, Schöffski P.

Br J Cancer. 2016 Apr 12;114(8):889-96. doi: 10.1038/bjc.2016.59. Epub 2016 Mar 22.


Phase 1b/2a study of trastuzumab emtansine (T-DM1), paclitaxel, and pertuzumab in HER2-positive metastatic breast cancer.

Krop IE, Modi S, LoRusso PM, Pegram M, Guardino E, Althaus B, Lu D, Strasak A, Elias A.

Breast Cancer Res. 2016 Mar 15;18(1):34. doi: 10.1186/s13058-016-0691-7.


Preclinical and first-in-human phase I studies of KW-2450, an oral tyrosine kinase inhibitor with insulin-like growth factor receptor-1/insulin receptor selectivity.

Schwartz GK, Dickson MA, LoRusso PM, Sausville EA, Maekawa Y, Watanabe Y, Kashima N, Nakashima D, Akinaga S.

Cancer Sci. 2016 Apr;107(4):499-506. doi: 10.1111/cas.12906. Epub 2016 Mar 28.


Phase I Study of PSMA-Targeted Docetaxel-Containing Nanoparticle BIND-014 in Patients with Advanced Solid Tumors.

Von Hoff DD, Mita MM, Ramanathan RK, Weiss GJ, Mita AC, LoRusso PM, Burris HA 3rd, Hart LL, Low SC, Parsons DM, Zale SE, Summa JM, Youssoufian H, Sachdev JC.

Clin Cancer Res. 2016 Jul 1;22(13):3157-63. doi: 10.1158/1078-0432.CCR-15-2548. Epub 2016 Feb 4.


Phase I Safety, Pharmacokinetic, and Pharmacodynamic Study of the Poly(ADP-ribose) Polymerase (PARP) Inhibitor Veliparib (ABT-888) in Combination with Irinotecan in Patients with Advanced Solid Tumors.

LoRusso PM, Li J, Burger A, Heilbrun LK, Sausville EA, Boerner SA, Smith D, Pilat MJ, Zhang J, Tolaney SM, Cleary JM, Chen AP, Rubinstein L, Boerner JL, Bowditch A, Cai D, Bell T, Wolanski A, Marrero AM, Zhang Y, Ji J, Ferry-Galow K, Kinders RJ, Parchment RE, Shapiro GI.

Clin Cancer Res. 2016 Jul 1;22(13):3227-37. doi: 10.1158/1078-0432.CCR-15-0652. Epub 2016 Feb 3.


A pharmacodynamically guided dose selection of PF-00337210 in a phase I study in patients with advanced solid tumors.

Bruce JY, LoRusso PM, Goncalves PH, Heath EI, Sadowski E, Shalinsky DR, Zhang Y, Traynor AM, Breazna A, Ricart AD, Tortorici M, Liu G.

Cancer Chemother Pharmacol. 2016 Mar;77(3):527-38. doi: 10.1007/s00280-016-2958-1. Epub 2016 Jan 20.


A phase I, first in human study of FP-1039 (GSK3052230), a novel FGF ligand trap, in patients with advanced solid tumors.

Tolcher AW, Papadopoulos KP, Patnaik A, Wilson K, Thayer S, Zanghi J, Gemo AT, Kavanaugh WM, Keer HN, LoRusso PM.

Ann Oncol. 2016 Mar;27(3):526-32. doi: 10.1093/annonc/mdv591. Epub 2015 Dec 8.


A phase I study of MK-5108, an oral aurora a kinase inhibitor, administered both as monotherapy and in combination with docetaxel, in patients with advanced or refractory solid tumors.

Amin M, Minton SE, LoRusso PM, Krishnamurthi SS, Pickett CA, Lunceford J, Hille D, Mauro D, Stein MN, Wang-Gillam A, Trull L, Lockhart AC.

Invest New Drugs. 2016 Feb;34(1):84-95. doi: 10.1007/s10637-015-0306-7. Epub 2015 Dec 1.


Next-Generation Sequencing to Guide Clinical Trials.

Siu LL, Conley BA, Boerner S, LoRusso PM.

Clin Cancer Res. 2015 Oct 15;21(20):4536-44. doi: 10.1158/1078-0432.CCR-14-3215. Review.


Advancing Clinical Trials to Streamline Drug Development.

Bates SE, Berry DA, Balasubramaniam S, Bailey S, LoRusso PM, Rubin EH.

Clin Cancer Res. 2015 Oct 15;21(20):4527-35. doi: 10.1158/1078-0432.CCR-15-0039.


Trastuzumab Emtansine (T-DM1) in Patients With HER2-Positive Metastatic Breast Cancer Previously Treated With Chemotherapy and 2 or More HER2-Targeted Agents: Results From the T-PAS Expanded Access Study.

Yardley DA, Krop IE, LoRusso PM, Mayer M, Barnett B, Yoo B, Perez EA.

Cancer J. 2015 Sep-Oct;21(5):357-64. doi: 10.1097/PPO.0000000000000144.


Pilot Trial of Selecting Molecularly Guided Therapy for Patients with Non-V600 BRAF-Mutant Metastatic Melanoma: Experience of the SU2C/MRA Melanoma Dream Team.

LoRusso PM, Boerner SA, Pilat MJ, Forman KM, Zuccaro CY, Kiefer JA, Liang WS, Hunsberger S, Redman BG, Markovic SN, Sekulic A, Bryce AH, Joseph RW, Cowey CL, Fecher LA, Sosman JA, Chapman PB, Schwartz GK, Craig DW, Carpten JD, Trent JM.

Mol Cancer Ther. 2015 Aug;14(8):1962-71. doi: 10.1158/1535-7163.MCT-15-0153. Epub 2015 Jun 10.


Phase I dose-escalation study of cabazitaxel administered in combination with gemcitabine in patients with metastatic or unresectable advanced solid malignancies.

Rixe O, Puzanov I, LoRusso PM, Cohen RB, Morris JC, Olowokure OO, Yin JY, Doroumian S, Shen L, Olszanski AJ.

Anticancer Drugs. 2015 Aug;26(7):785-92. doi: 10.1097/CAD.0000000000000250.


A Phase I dose-escalation study of afatinib combined with nintedanib in patients with advanced solid tumors.

Gordon MS, Springett GM, Su YB, Ould-Kaci M, Wind S, Zhao Y, LoRusso PM.

Future Oncol. 2015;11(10):1479-91. doi: 10.2217/fon.15.50.


Protein expression of DNA damage repair proteins dictates response to topoisomerase and PARP inhibitors in triple-negative breast cancer.

Boerner JL, Nechiporchik N, Mueller KL, Polin L, Heilbrun L, Boerner SA, Zoratti GL, Stark K, LoRusso PM, Burger A.

PLoS One. 2015 Mar 16;10(3):e0119614. doi: 10.1371/journal.pone.0119614. eCollection 2015.


First-in-human phase 1 study of filanesib (ARRY-520), a kinesin spindle protein inhibitor, in patients with advanced solid tumors.

LoRusso PM, Goncalves PH, Casetta L, Carter JA, Litwiler K, Roseberry D, Rush S, Schreiber J, Simmons HM, Ptaszynski M, Sausville EA.

Invest New Drugs. 2015 Apr;33(2):440-9. doi: 10.1007/s10637-015-0211-0. Epub 2015 Feb 17.


An integrated framework for reporting clinically relevant biomarkers from paired tumor/normal genomic and transcriptomic sequencing data in support of clinical trials in personalized medicine.

Nasser S, Kurdolgu AA, Izatt T, Aldrich J, Russell ML, Christoforides A, Tembe W, Keifer JA, Corneveaux JJ, Byron SA, Forman KM, Zuccaro C, Keats JJ, Lorusso PM, Carpten JD, Trent JM, Craig DW.

Pac Symp Biocomput. 2015:56-67.


Phase I study of XL281 (BMS-908662), a potent oral RAF kinase inhibitor, in patients with advanced solid tumors.

Dickson MA, Gordon MS, Edelman G, Bendell JC, Kudchadkar RR, LoRusso PM, Johnston SH, Clary DO, Schwartz GK.

Invest New Drugs. 2015 Apr;33(2):349-56. doi: 10.1007/s10637-014-0191-5. Epub 2014 Dec 5.


Assessment of the drug interaction potential and single- and repeat-dose pharmacokinetics of the BRAF inhibitor dabrafenib.

Suttle AB, Grossmann KF, Ouellet D, Richards-Peterson LE, Aktan G, Gordon MS, LoRusso PM, Infante JR, Sharma S, Kendra K, Patel M, Pant S, Arkenau HT, Middleton MR, Blackman SC, Botbyl J, Carson SW.

J Clin Pharmacol. 2015 Apr;55(4):392-400. doi: 10.1002/jcph.437. Epub 2014 Dec 30.


A Phase I, dose-finding study in patients with advanced solid malignancies of the oral γ-secretase inhibitor PF-03084014.

Messersmith WA, Shapiro GI, Cleary JM, Jimeno A, Dasari A, Huang B, Shaik MN, Cesari R, Zheng X, Reynolds JM, English PA, McLachlan KR, Kern KA, LoRusso PM.

Clin Cancer Res. 2015 Jan 1;21(1):60-7. doi: 10.1158/1078-0432.CCR-14-0607. Epub 2014 Sep 17.


Design of phase I combination trials: recommendations of the Clinical Trial Design Task Force of the NCI Investigational Drug Steering Committee.

Paller CJ, Bradbury PA, Ivy SP, Seymour L, LoRusso PM, Baker L, Rubinstein L, Huang E, Collyar D, Groshen S, Reeves S, Ellis LM, Sargent DJ, Rosner GL, LeBlanc ML, Ratain MJ.

Clin Cancer Res. 2014 Aug 15;20(16):4210-7. doi: 10.1158/1078-0432.CCR-14-0521. Review.


Phase I first-in-human study of CUDC-101, a multitargeted inhibitor of HDACs, EGFR, and HER2 in patients with advanced solid tumors.

Shimizu T, LoRusso PM, Papadopoulos KP, Patnaik A, Beeram M, Smith LS, Rasco DW, Mays TA, Chambers G, Ma A, Wang J, Laliberte R, Voi M, Tolcher AW.

Clin Cancer Res. 2014 Oct 1;20(19):5032-40. doi: 10.1158/1078-0432.CCR-14-0570. Epub 2014 Aug 8.


Carlumab, an anti-C-C chemokine ligand 2 monoclonal antibody, in combination with four chemotherapy regimens for the treatment of patients with solid tumors: an open-label, multicenter phase 1b study.

Brana I, Calles A, LoRusso PM, Yee LK, Puchalski TA, Seetharam S, Zhong B, de Boer CJ, Tabernero J, Calvo E.

Target Oncol. 2015 Mar;10(1):111-23. doi: 10.1007/s11523-014-0320-2. Epub 2014 Jun 15.


Trastuzumab emtansine versus treatment of physician's choice for pretreated HER2-positive advanced breast cancer (TH3RESA): a randomised, open-label, phase 3 trial.

Krop IE, Kim SB, González-Martín A, LoRusso PM, Ferrero JM, Smitt M, Yu R, Leung AC, Wildiers H; TH3RESA study collaborators.

Lancet Oncol. 2014 Jun;15(7):689-99. doi: 10.1016/S1470-2045(14)70178-0. Epub 2014 May 2.


A phase I study of oral ixabepilone in patients with advanced solid tumors.

Deeken JF, Marshall JL, Pishvaian MJ, Hwang J, Ahlers CM, Clemens PL, Parker SM, Iacono L, LoRusso PM.

Cancer Chemother Pharmacol. 2014 May;73(5):1071-8. doi: 10.1007/s00280-014-2443-7. Epub 2014 Mar 25.


A Phase Ib study evaluating MNRP1685A, a fully human anti-NRP1 monoclonal antibody, in combination with bevacizumab and paclitaxel in patients with advanced solid tumors.

Patnaik A, LoRusso PM, Messersmith WA, Papadopoulos KP, Gore L, Beeram M, Ramakrishnan V, Kim AH, Beyer JC, Mason Shih L, Darbonne WC, Xin Y, Yu R, Xiang H, Brachmann RK, Weekes CD.

Cancer Chemother Pharmacol. 2014 May;73(5):951-60. doi: 10.1007/s00280-014-2426-8. Epub 2014 Mar 17.


Phase I safety, pharmacokinetic, and pharmacodynamic study of SAR245409 (XL765), a novel, orally administered PI3K/mTOR inhibitor in patients with advanced solid tumors.

Papadopoulos KP, Tabernero J, Markman B, Patnaik A, Tolcher AW, Baselga J, Shi W, Egile C, Ruiz-Soto R, Laird AD, Miles D, Lorusso PM.

Clin Cancer Res. 2014 May 1;20(9):2445-56. doi: 10.1158/1078-0432.CCR-13-2403. Epub 2014 Feb 28.


Phase I study of PF-04691502, a small-molecule, oral, dual inhibitor of PI3K and mTOR, in patients with advanced cancer.

Britten CD, Adjei AA, Millham R, Houk BE, Borzillo G, Pierce K, Wainberg ZA, LoRusso PM.

Invest New Drugs. 2014 Jun;32(3):510-7. doi: 10.1007/s10637-013-0062-5. Epub 2014 Jan 7. Erratum in: Invest New Drugs. 2014 Jun;32(3):575.


The intersection of immune-directed and molecularly targeted therapy in advanced melanoma: where we have been, are, and will be.

Sullivan RJ, Lorusso PM, Flaherty KT.

Clin Cancer Res. 2013 Oct 1;19(19):5283-91. doi: 10.1158/1078-0432.CCR-13-2151. Review.

Supplemental Content

Loading ...
Support Center